In the Order of 19 July 2021 (ECLI:ES:JMB:2021:2692A) Commercial Court No. 1 of Barcelona dismissed a preliminary injunction request by BAYER against four companies that launched generic medicines containing the active ingredient sorafenib in the form of its tosylate salt on the Spanish market.
An in depth study on the ongoing Standard Essential Patents (SEP) reform in the frame of the European Commission’s innovation promotion policy supported by a Pilot Study.
[et_pb_section fb_built=”1″ _builder_version=”3.19.5″][et_pb_row _builder_version=”3.0.48″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”2_5″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_image src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2021/05/VQR_LAW_NEW38.jpg” _builder_version=”3.19.5″][/et_pb_image][/et_pb_column][et_pb_column type=”3_5″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_post_title comments=”off” featured_image=”off” _builder_version=”3.19.5″][/et_pb_post_title][et_pb_text _builder_version=”3.19.5″] The Commercial Court No. 5 of Barcelona has declared the Supplementary Protection Certificate (“SPC”) of Merck Sharp & Dohme Corporation (“MSD”) null and void in a judgment dated 21 April 2021. Background As we ...
[et_pb_section fb_built=”1″ _builder_version=”3.19.5″][et_pb_row _builder_version=”3.0.48″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”2_5″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_image src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2021/05/VQR_LAW_NEW36b.jpg” _builder_version=”3.19.5″][/et_pb_image][/et_pb_column][et_pb_column type=”3_5″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_post_title comments=”off” featured_image=”off” _builder_version=”3.19.5″][/et_pb_post_title][et_pb_text _builder_version=”3.19.5″] On 25 March 2021 I took part in the Matinal IP & Competencia conference that is held once a month by the Competition and Industrial Property Law Section of the Barcelona Bar Association; this ...
[et_pb_section bb_built=”1″ _builder_version=”3.19.5″][et_pb_row][et_pb_column type=”2_5″][et_pb_image _builder_version=”3.19.5″ src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2021/02/VQR_LAW_NEW34.jpg” /][/et_pb_column][et_pb_column type=”3_5″][et_pb_post_title _builder_version=”3.19.5″ comments=”off” featured_image=”off” /][et_pb_text _builder_version=”3.19.5″] In some recent and interesting proceedings, a Central Contentious Administrative Court in Madrid refused to provide further information contained in the administrative files of two pharmaceutical companies (codefendants) and hence the confidential information could not be obtained that was included in the ...
[et_pb_section bb_built=”1″ _builder_version=”3.19.5″][et_pb_row][et_pb_column type=”2_5″][et_pb_image _builder_version=”3.19.5″ src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2020/07/VQR_LAW_NEW29.jpg” /][/et_pb_column][et_pb_column type=”3_5″][et_pb_post_title _builder_version=”3.19.5″ comments=”off” featured_image=”off” author=”off” /][et_pb_text _builder_version=”3.19.5″] BY SONIA SARROCA, NÚRIA COLL AND ORIOL RAMON The Judgment of the Barcelona Court of Appeal (Section 15) No. 477/2020 of 15 January (ECLI:ES:APB:2020:477) confirmed the validity, already declared in the first instance, of a patent on a pharmaceutical formulation for administration ...
[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”2_5″][et_pb_image _builder_version=”3.19.5″ src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2020/03/VQR_LAW_NEW23.jpg” /][/et_pb_column][et_pb_column type=”3_5″][et_pb_post_title _builder_version=”3.19.5″ featured_image=”off” /][et_pb_text _builder_version=”3.19.5″] On Friday 20 March, the German Bundesverfassungsgericht, the Federal Constitutional Court, published its Decision of 13 February 2020. This decision states that the Act of Approval to the Agreement on a Unified Patent Court, which conferred sovereign powers on the Unified Patent Court, is ...
[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”2_5″][et_pb_image _builder_version=”3.19.5″ src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2020/02/VQR_LAW_NEW21-2.jpg” /][/et_pb_column][et_pb_column type=”3_5″][et_pb_post_title _builder_version=”3.19.5″ comments=”off” featured_image=”off” /][et_pb_text _builder_version=”3.19.5″] The Commercial Court No. 5 of Barcelona has recently needed to uphold that the civil/commercial courts are competent to decide on actions for invalidity of Supplementary Protection Certificates (hereinafter, SPCs). Background Merck Sharp & Dohme Corporation, the holder of an SPC for a ...
[et_pb_section bb_built=”1″ _builder_version=”3.19.5″][et_pb_row][et_pb_column type=”2_5″][et_pb_image _builder_version=”3.19.5″ src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2020/01/VQR_LAW_NEW20B-2.jpg” /][/et_pb_column][et_pb_column type=”3_5″][et_pb_post_title _builder_version=”3.19.5″ comments=”off” featured_image=”off” /][et_pb_text _builder_version=”3.19.5″] According to the Spanish Civil Procedural Act (CPA), there are two requirements that need to be met in order to obtain preliminary injunctions in the Spanish Courts: danger in delay (periculum in mora) and the presumption of good right (fumus boni iuris). ...
[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”2_5″][et_pb_image _builder_version=”3.19.5″ src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2019/12/VQR_LAW_NEW18.jpg” /][/et_pb_column][et_pb_column type=”3_5″][et_pb_post_title _builder_version=”3.19.5″ comments=”off” featured_image=”off” /][et_pb_text _builder_version=”3.19.5″] One more year, Barcelona is about to become the world capital of technology thanks to the new edition of the Mobile World Congress (MWC) that will take place from February 24 to 27, 2020. Faced with the possibility of conflicts that might arise ...
